LADY PLASABAS: Open Payments
NPI 1972331023 · EAST CHICAGO, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,595 in 72 payments from 21 companies in 2025. Trend: 2023 $0 · 2024 $164 · 2025 $1,595
Food & beverage: $1,595
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 8 | $219 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $210 |
| Xeris Pharmaceuticals, Inc. | 9 | $175 |
| Lilly USA, LLC | 7 | $144 |
| RECORDATI_RARE_DISEASES_INC. | 8 | $142 |
| Amgen Inc. | 4 | $112 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $102 |
| Novo Nordisk Inc | 5 | $96 |
| Sumitomo Pharma America, Inc. | 3 | $63 |
| Radius Health, Inc. | 2 | $50 |
Products named: REZDIFFRA, Kerendia, ISTURISA, GVOKE HYPOPEN, TEPEZZA, XIFAXAN, GEMTESA, Tymlos.
Industry payments across IN — which companies pay providers there.
